These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 11904782)

  • 21. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.
    García-Carbonero R; Mayordomo JI; Tornamira MV; López-Brea M; Rueda A; Guillem V; Arcediano A; Yubero A; Ribera F; Gómez C; Trés A; Pérez-Gracia JL; Lumbreras C; Hornedo J; Cortés-Funes H; Paz-Ares L
    J Natl Cancer Inst; 2001 Jan; 93(1):31-8. PubMed ID: 11136839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
    Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN
    J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.
    Cosler LE; Eldar-Lissai A; Culakova E; Kuderer NM; Dale D; Crawford J; Lyman GH
    Pharmacoeconomics; 2007; 25(4):343-51. PubMed ID: 17402806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
    Rusthoven J; Bramwell V; Stephenson B
    Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia. Results of a randomised placebo-controlled trial.
    Uyl-de Groot CA; Vellenga E; de Vries EG; Löwenberg B; Stoter GJ; Rutten FF
    Pharmacoeconomics; 1997 Sep; 12(3):351-60. PubMed ID: 10170460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients.
    Mitchell PL; Morland B; Stevens MC; Dick G; Easlea D; Meyer LC; Pinkerton CR
    J Clin Oncol; 1997 Mar; 15(3):1163-70. PubMed ID: 9060560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials.
    Wittman B; Horan J; Lyman GH
    Cancer Treat Rev; 2006 Jun; 32(4):289-303. PubMed ID: 16678350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of granulocyte colony-stimulating factors in the treatment of established febrile neutropenia.
    Pérez Velasco R
    J Oncol Pharm Pract; 2011 Sep; 17(3):225-32. PubMed ID: 20562168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
    Ozkaynak MF; Krailo M; Chen Z; Feusner J
    Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): an appraisal of its pharmacoeconomic status in neutropenia associated with chemotherapy and autologous bone marrow transplant.
    Goa KL; Bryson HM
    Pharmacoeconomics; 1994 Jan; 5(1):56-77. PubMed ID: 10146867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Colony-stimulating factors for the management of neutropenia in cancer patients.
    Dale DC
    Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study.
    Thomas X; Boiron JM; Huguet F; Reman O; Sutton L; Turlure P; Garban F; Gardin C; Espinouse D; Boulat O; Lhéritier V; Fiere D;
    Hematol J; 2004; 5(5):384-94. PubMed ID: 15448664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Febrile neutropenia, colony-stimulating factors and therapy: time for a new methodology?
    Forrest GN; Schimpff SC; Cross A
    Support Care Cancer; 2002 Apr; 10(3):177-80. PubMed ID: 11904781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis.
    Berghmans T; Paesmans M; Lafitte JJ; Mascaux C; Meert AP; Sculier JP
    Lung Cancer; 2002 Aug; 37(2):115-23. PubMed ID: 12140132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
    Kuderer NM; Dale DC; Crawford J; Lyman GH
    J Clin Oncol; 2007 Jul; 25(21):3158-67. PubMed ID: 17634496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia.
    Gómez Raposo C; Pinto Marín A; González Barón M
    Clin Transl Oncol; 2006 Oct; 8(10):729-34. PubMed ID: 17074671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
    Bregni M; Siena S; Di Nicola M; Dodero A; Peccatori F; Ravagnani F; Danesini G; Laffranchi A; Bonadonna G; Gianni AM
    J Clin Oncol; 1996 Feb; 14(2):628-35. PubMed ID: 8636780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outpatient management of the febrile neutropenic child with cancer.
    Patrick CC; Shenep JL
    Adv Pediatr Infect Dis; 1999; 14():29-47. PubMed ID: 10079848
    [No Abstract]   [Full Text] [Related]  

  • 40. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity.
    Johnston EM; Crawford J
    Semin Oncol; 1998 Oct; 25(5):552-61. PubMed ID: 9783594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.